A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects with Mild to Moderate Ulcerative Colitis

Trial Profile

A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects with Mild to Moderate Ulcerative Colitis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs VB 201 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors VBL Therapeutics
  • Most Recent Events

    • 17 Feb 2015 According to a media release, VB-201 in patients with ulcerative colitis did not meet its primary endpoint; VBL Therapeutics does not plan to continue development of VB-201 in this indication.
    • 17 Feb 2015 Primary endpoint of 'modified mayo score indicating remission at week 12 and week 24' has not been met, according to a VBL Therapeutics media release.
    • 17 Feb 2015 Top-line results published in a VBL Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top